Company news
AnaptysBio, Inc. news in 2021
AnaptysBio, Inc.'s news releases, calls and decks from 2021, newest first.
AnaptysBio Announces Appointment of Daniel Faga to Board of Directors
November 28, 2021
AnaptysBio To Present at the 2021 Jefferies London Healthcare Conference
November 14, 2021
AnaptysBio Announces Positive Rosnilimab Healthy Volunteer Phase 1 Top-Line Data
November 14, 2021
AnaptysBio Announces Third Quarter 2021 Financial Results and Provides Pipeline Updates
November 3, 2021
AnaptysBio Announces Agreement to Monetize Portion of JEMPERLI Royalties for $250 Million with Sagard
October 24, 2021
AnaptysBio Presents Updated Data From Imsidolimab Phase 2 GALLOP Trial in Generalized Pustular Psoriasis
October 1, 2021
AnaptysBio to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
September 8, 2021
FDA Grants Accelerated Approval of JEMPERLI (dostarlimab-gxly) for dMMR Recurrent or Advanced Solid Tumors
August 16, 2021
AnaptysBio Announces Second Quarter 2021 Financial Results and Provides Pipeline Updates
August 8, 2021
AnaptysBio to Present at the 2021 Jefferies Virtual Healthcare Conference
May 26, 2021
AnaptysBio Announces First Quarter 2021 Financial Results and Provides Pipeline Updates
May 3, 2021
AnaptysBio Announces Appointment of Oleg Nodelman to Board of Directors
April 11, 2021
AnaptysBio Reports Imsidolimab POPLAR Phase 2 Clinical Trial in Moderate-to-Severe Palmoplantar Pustulosis (PPP) Did Not Meet Primary Endpoint
March 7, 2021
AnaptysBio Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Pipeline Updates
February 24, 2021
AnaptysBio to Present at the 39th Annual J.P. Morgan Healthcare Conference
January 6, 2021
Decks in 2021
- Jefferies Virtual Healthcare Conference 2021
Conference · 33 slides · Jun 3, 2021
- 39th Annual J.P. Morgan Healthcare Conference 2021
Conference · 35 slides · Jan 11, 2021